Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q1 2026 · 10-Q
Revenue$722.52M$722.52M+3.9% vs Q1 2025 Net Income$62.26M$62.26M+410.5% vs Q1 2025 EPS Diluted$0.19$0.19+375.0% vs Q1 2025 Gross Profit$320,113,000+25.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flow-$26,743,000N/M Free Cash Flowderived-$34,918,000N/M Margins · derivedGross margin44.3%+7.5 pt vs Q1 2025
Operating margin19.6%+5.2 pt vs Q1 2025
Net margin8.6%+6.9 pt vs Q1 2025
ended Mar 31, 2026 · filed May 7, 2026 · 37 d after period end